Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

PTSH, AMLN, HOLX, TIVO - Weekend Stock Review

|Includes: TiVo Inc. (TIVO)

PTS Inc. (OTCPK:PTSH) entered into a Share Exchange Agreement pursuant to which PTSH will acquire 70% of ThinLine Technology Group at the closing. Closing shall occur as soon as PTSH receives satisfactory audited financials from ThinLine, but not later than December 31, 2010.

ThinLine Technology Group manages, markets and maintains the IT and VOIP infrastructure for small and medium business and provides Private Cable Operators, private label billing and call center support. At present, the company services over 21,000 clients on behalf of Private Cable Operators over 400 apartment properties across the United States.

For more information about this company please visit


Amylin Pharmaceuticals, Inc. (Nasdaq:AMLN) on Thursday November 4, 2010 reported a smaller-than-expected loss in its fiscal second quarter amid higher manufacturing revenue and sales and royalty payments.
The company, however, slashed its forecast for fiscal 2011 following last month’s rejection of diabetes drug candidate Bydureon by federal regulators. Alkermes is working together with Eli Lilly and Co. and Amylin Pharmaceuticals Inc. to develop the drug.
Amylin Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug candidates for the treatment of diabetes, obesity, and other diseases.


Hologic Inc. (Nasdaq:HOLX) a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, announced on November 1, 2010 the long-term, five-year results from the American Society of Breast Surgeons (ASBS) MammoSite® Breast Brachytherapy Registry Trial (ASBS Registry) while showcasing the MammoSite ML (multi-lumen) system at the 52nd ASTRO (American Society for Radiation Oncology) Annual Meeting in San Diego October 31 through November 4, 2010. The ASBS Registry Trial represents the largest compilation of MammoSite patients to date and demonstrates promising results for breast cancer patients. The MammoSite system is the only breast brachytherapy balloon with five-year efficacy data. Of the 1,449 patients (1,440 treated) with early-stage breast cancer, 37 patients had an ipsilateral breast tumor recurrence (IBTR), for a five-year actuarial rate of 3.80 percent. A subset analysis of the first 400 consecutive cases had a median follow-up of 60.5 months and demonstrated a five-year actuarial rate of IBTR of 3.04 percent.
Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic’s core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health.


TiVo Inc. (Nasdaq:TIVO) a leader in advanced television services and advertising solutions for digital video recorders (DVRs), announced on November 3, 2010 audience measurement results that identify how effective this fall season’s on-air broadcast television promos were in driving viewers to tune-in over the course of the last three months. Using ‘Promo Effectiveness’ viewing data from TiVo’s Power||Watch™ ratings service, which consists of an opt-in panel of 35,000 TiVo subscribers, TiVo was able to analyze the efficacy of each network’s promo spots — an invaluable tool for networks to have for understanding how to improve the use of their on-air inventory to drive larger audiences to their programs.
Founded in 1997, TiVo Inc. (NASDAQ:TIVO) developed the first commercially available digital video recorder (NYSE:DVR). TiVo offers the TiVo service and TiVo DVRs directly to consumers online at and through third-party retailers.



Sign-Up For Free Stock Alerts At



Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.The publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer ( ) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. ( read more at ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (OTCPK:CRWE) has received five thousand dollars and anticipates receiving another forty five thousand dollars in cash from a third party for (thirty) days of advertising for PTS Inc. (OTCPK:PTSH).